NASDAQ:DYAX - Dyax Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$38.41
Today's Range$38.41 - $38.41
52-Week Range$14.06 - $38.56
VolumeN/A
Average Volume5.25 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Dyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, it discovered and is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. It also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. The Company has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development.

Receive DYAX News and Ratings via Email

Sign-up to receive the latest news and ratings for DYAX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:DYAX
CUSIP26746E10
Phone+1-617-2505769

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Dyax (NASDAQ:DYAX) Frequently Asked Questions

What is Dyax's stock symbol?

Dyax trades on the NASDAQ under the ticker symbol "DYAX."

How were Dyax's earnings last quarter?

Dyax Corp. (NASDAQ:DYAX) announced its earnings results on Wednesday, October, 28th. The biopharmaceutical company reported ($0.08) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.08). The biopharmaceutical company earned $24.70 million during the quarter, compared to the consensus estimate of $24.96 million. The business's revenue was up 12.3% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.01) earnings per share. View Dyax's Earnings History.

Has Dyax been receiving favorable news coverage?

News articles about DYAX stock have trended somewhat negative on Thursday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Dyax earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term.

What other stocks do shareholders of Dyax own?

How do I buy shares of Dyax?

Shares of DYAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dyax's official website?

The official website for Dyax is http://www.dyax.com.

How can I contact Dyax?

Dyax's mailing address is 55 Network Dr, BURLINGTON, MA 01803-2756, United States. The biopharmaceutical company can be reached via phone at +1-617-2505769.


MarketBeat Community Rating for Dyax (NASDAQ DYAX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  208 (Vote Outperform)
Underperform Votes:  149 (Vote Underperform)
Total Votes:  357
MarketBeat's community ratings are surveys of what our community members think about Dyax and other stocks. Vote "Outperform" if you believe DYAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DYAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel